Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02 July 2024 - 6:05AM
Verve Therapeutics, a clinical-stage biotechnology company
pioneering a new approach to the care of cardiovascular disease
with single-course gene editing medicines, today announced that on
June 28, 2024, the company granted equity awards to one new
employee, pursuant to the company’s 2024 Inducement Stock Incentive
Plan, as an inducement material to such new employee entering into
employment with the company in accordance with Nasdaq Listing Rule
5635(c)(4).
The employee received a stock option to purchase 76,900 shares
of the company’s common stock and 19,200 restricted stock units
(RSUs). The option has an exercise price of $4.88 per share, which
is equal to the closing price of the company’s common stock on the
date of grant. Such option has a 10-year term and will vest over a
period of four years, with 25% of the shares vesting on the
one-year anniversary of the grant date and the remainder vesting in
equal monthly installments over the following three years, subject
to such employee’s continued service with the company on each such
vesting date. The RSUs will vest in equal annual installments on
the first four anniversaries of July 1, 2024, subject to such
employee’s continued service with the company on each such vesting
date.
About Verve Therapeutics Verve
Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic
medicines company pioneering a new approach to the care of
cardiovascular disease, potentially transforming treatment from
chronic management to single-course gene editing medicines. The
company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 –
target genes that have been extensively validated as targets for
lowering low-density lipoprotein cholesterol (LDL-C), a root cause
of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and
VERVE-102 are designed to permanently turn off
the PCSK9 gene in the liver and are being developed
initially for heterozygous familial hypercholesterolemia (HeFH) and
ultimately to treat patients with established ASCVD who continue to
be impacted by high LDL-C levels. VERVE-201 is designed to
permanently turn off the ANGPTL3 gene in the liver and is
initially being developed for homozygous familial
hypercholesterolemia (HoFH) and for refractory hypercholesterolemia
where patients still have high LDL-C despite treatment with
maximally-tolerated standard of care therapies. For more
information, please visit www.VerveTx.com.
Investor ContactJen RobinsonVerve Therapeutics,
Inc.jrobinson@vervetx.com
Media ContactAshlea
Kosikowski1ABashlea@1abmedia.com
Verve Therapeutics (NASDAQ:VERV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verve Therapeutics (NASDAQ:VERV)
Historical Stock Chart
From Jul 2023 to Jul 2024